Novo Nordisk A/S $NVO Shares Acquired by Beacon Financial Group

Beacon Financial Group grew its position in Novo Nordisk A/S (NYSE:NVO) by 43.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,129 shares of the company’s stock after acquiring an additional 1,245 shares during the period. Beacon Financial Group’s holdings in Novo Nordisk A/S were worth $285,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. First Hawaiian Bank raised its position in shares of Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock worth $1,556,000 after acquiring an additional 142 shares during the period. Anchor Investment Management LLC raised its position in shares of Novo Nordisk A/S by 1.1% in the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after acquiring an additional 150 shares during the period. Xponance Inc. raised its position in shares of Novo Nordisk A/S by 5.0% in the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after acquiring an additional 158 shares during the period. Foster Dykema Cabot & Partners LLC raised its position in shares of Novo Nordisk A/S by 3.8% in the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock worth $319,000 after acquiring an additional 166 shares during the period. Finally, 180 Wealth Advisors LLC raised its position in shares of Novo Nordisk A/S by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company’s stock worth $348,000 after acquiring an additional 173 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $57.19 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock has a market capitalization of $255.35 billion, a P/E ratio of 15.71, a PEG ratio of 2.11 and a beta of 0.66. The company has a 50 day moving average price of $57.44 and a 200 day moving average price of $65.86. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $135.20.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday. UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Finally, HSBC downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price target for the company. in a research report on Thursday, July 31st. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.